SCIEnTIFIC ADvISoRy BoARD

Lynn A. RAyMonD, MD, PHD, FRCPC

Director, Djavad Mowafaghian Centre for Brain Health

Professor, Department of Psychiatry, Faculty of Medicine

Louise A. Brown Chair in Neuroscience

Associate Member, Department of Medicine, Division of Neurology

Associate Member, Department of Cellular and Physiological Sciences

University of British Columbia

Dr. Lynn Raymond is a clinician-scientist who trained at Albert Einstein College of Medicine and Johns Hopkins Medical Institutions. She was recruited to the University of British Columbia (UBC) in 1994 where she combines neuroscience research with clinical practice in neurology. She leads a research lab funded by the Canadian Institutes of Health Research (CIHR) and is Clinic Director of the Centre for Huntington Disease.

For many years she has investigated the roles of altered neuronal circuits, synapses and NMDA-type glutamate receptors in Huntington’s disease with the goal of finding therapeutics that slow progression. More recently, Dr. Raymond’s work focuses on changes in cortical and striatal synaptic plasticity and circuit function that may underlie early cognitive and sensorimotor deficits and could contribute to neuronal vulnerability to degeneration.

Dr. Raymond has served as UBC site investigator for several multi-center clinical research studies in Huntington’s disease. Currently, Dr. Raymond serves as Director of the Djavad Mowafaghian Centre for Brain Health at UBC.

H. DIAnA RoSAS, MD

Associate Professor, Departments of Neurology and Radiology

Director, Center for Neuro-imaging of Aging and Neurodegenerative Disease

Massachusetts General Hospital, Harvard Medical School

Dr. H. Diana Rosas focuses primarily on the development of biomarkers for use in the study of neurodegenerative diseases to better characterize progression, to better understand genotype/phenotype correlations, and to apply novel neuro-imaging approaches in clinical trials with the overall aim of making the trials more efficient.

Dr. Rosas and her team have begun to develop models that may explain clinically heterogeneous phenotypes and variability in disease progression. They plan to expand their efforts to include several different types of imaging approaches that promise more precise measurements and may provide novel and important information on the neural underpinnings of HD and their clinical consequences.